|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ''Brugada'' syndrome clinical data and suggested pathophysiological mechanism显示文摘 | Alings M Wilde A | 1999 | Circulation1999，99，3： | 1 |
| 2 | Classifieation and manage- ment of early complications in open lumbar microdiscectomy显示文摘 | Kraemer R Wild A Flaak H el al | 2003 | Eur Spine J2003，12，3： | 1 |
| 3 | Distribution of of porcine circovi- boars and domestic pigs in Germany显示文摘 | Reiner G Bronnert B et ORF2 and ORF3 genotypes rus type2(PCV2) in wild al | 2011 | Vet Microbiol2011，148，37： | 1 |
| 4 | The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases显示文摘 | Pillay V Allaf L Wilding AL | 2009 | Neoplasia2009，11，5： | 1 |
| 5 | Radioiodine therapy of benign thy-roid disorders: what are the effective thyroidal half-life and uptake of 31I? 显示文摘 | Kobe C Eschner W Wild M ct al | 2010 | Nucl Med Commun2010，31，3： | 1 |
| 6 | 显示文摘 | Alings M Wilde A | 1999 | Circulation1999，99，5： | 1 |
| 7 | Silencing of cyclooxy- genase-2 inhibits metastasis and delays tumor onset of poorly differ- entiated metastatic breast cancer cells显示文摘 | Stasinopoulos 1 O'Brien DR Wildes F ct al | 2007 | Mol Cancer Res2007，5，5： | 1 |
| 8 | Global prevalence of diabetes:estim ates for the year 2000 and projections for 2030显示文摘 | Wild S Roglic G Green A et al | 2004 | Diaberes Care:2004，27，： | 1 |
| 9 | Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study显示文摘BACKGROUND Biologic therapy resulted in a significant positive impact on the management of inflammatory bowel disease(IBD) however data on the efficacy and side effects of these therapies in the elderly is scant.AIM To evaluate retrospectively the drug sustainability, effectiveness, and safety of the biologic therapies in the elderly IBD population.METHODS Consecutive elderly(≥ 60 years old) IBD patients, treated with biologics [infliximab(IFX), adalimumab(ADAL), vedolizumab(VDZ), ustekinumab(UST)] followed at the McGill University Inflammatory Bowel Diseases Center were included between January 2000 and 2020.Efficacy was measured by clinical scores at 3, 6-9 and 12-18 mo after initiation of the biologic therapy. Patients completing induction therapy were included. Adverse events(AEs) or serious AE were collected during and within three months of stopping of the biologic therapy.RESULTS We identified a total of 147 elderly patients with IBD treated with biologicals during the study period, including 109 with Crohn’s disease and 38 with ulcerative colitis. Patients received the following biologicals: IFX(28.5%), ADAL(38.7%), VDZ(15.6%), UST(17%). The mean duration of biologic treatment was 157.5(SD = 148) wk. Parallel steroid therapy was given in 34% at baseline,19% at 3 mo, 16.3% at 6-9 mo and 6.5% at 12-18 mo. The remission rates at 3, 6-9 and 12-18 mo were not significantly different among biological therapies. Kaplan-Meyer analysis did not show statistical difference for drug sustainability(P = 0.195), time to adverse event(P = 0.158) or infection rates(P = 0.973) between the four biologics studied. The most common AEs that led to drug discontinuation were loss of response, infusion/injection reaction and infection.CONCLUSION Current biologics were not different regarding drug sustainability, effectiveness, and safety in the elderly IBD population. Therefore, we are not able to suggest a preferred sequencing order among biologicals. | Gustavo Drugg Hahn Jean-Frederic LeBlanc Petra Anna Golovics Panu Wetwittayakhlang Abdulrahman Qatomah Anna Wang Levon Boodaghians Jeremy Liu Chen Kiow Maryam Al Ali Gary Wild Waqqas Afif Alain Bitton Peter Laszlo Lakatos Talat Bessissow | 2022 | World Journal of Gastroenterology2022，28，33： | 1 |
| 10 | Therapy-induced senescence in cancer显示文摘 | Ewald JA Desotelle JA Wilding G el al | 2010 | J Natl Cancer Inst2010，102，22： | 1 |
| 11 | Comparison of classic and endoscopic lymphadcnectomy for staging breast cancer显示文摘 | de Wilde RL Schmidt EH Hesseling M el al | 2003 | J Am Assoc Gynecol Laparosc2003，10，1： | 1 |
| 12 | Standard surgical protocolto treat elbow dislocations with radial head and coronoid fractures显示文摘 | Pugh DM Wild LM Schemitsch EH ef al | 2004 | J Bone Joint Surg (Am)2004，86，6： | 1 |
| 13 | Development of a new engineeringbased capsule for human drug absorption studies 显示文摘 | Wilding IR Hirst PH Connor AL | 2000 | Pharm Sci Technol Today2000，3，11： | 1 |
| 14 | Emotion regulation, affect, psychosoeial functiong,and well-being in hemodialysis patients显示文摘 | Gillander S Wild M Deighan C ct al | 2008 | Am J Kidney Dis2008，51，4： | 1 |
| 15 | 'Brugada'syndrome clinical data and suggested pathophysiological mechanism显示文摘 | Alings M Wilde A | 1999 | Circulation1999，99，： | 1 |
| 16 | Brugada syndrome:Clinical data and suggested pathophysiological mechanism显示文摘 | Wilde A | 1999 | Circulation1999，99，： | 1 |
| 17 | Scintigraphic eval- uation of a novel colon-targeted delivery system (CODES) in healthy volunteers 显示文摘 | KATSUMA M CONNOR AL WILDING IR | 2004 | J Pharm Sci2004，93，5： | 1 |
| 18 | Global prevalence of diabetes: estimates for the year 2000 and projections or 2030显示文摘 | Wild S Roglic G Gren A Et al | 2004 | Diabetes Care2004，27，5： | 1 |
| 19 | Using the Enterion Capsule to Investigate the Absorption of Faropenem Daloxate Delivered in Particulate Form From Diff Erent Sites in the Gastrointestinal Tract显示文摘 | Connor AL Wray HA Voith B Voigt U Nagelschmitz J Kuhlmann J Wilding IR | 2001 | Pharm Sci2001，3，3： | 1 |
| 20 | 'Brugada' syndrome clinical data and suggested pat hophysiological mechanism显示文摘 | Wilde A | 1999 | Circulation1999，99，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员